Brokerages Anticipate Acorda Therapeutics Inc (ACOR) Will Post Earnings of -$0.72 Per Share

Equities research analysts expect that Acorda Therapeutics Inc (NASDAQ:ACOR) will report ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Acorda Therapeutics’ earnings, with estimates ranging from ($1.20) to $0.13. Acorda Therapeutics reported earnings of $0.61 per share in the same quarter last year, which indicates a negative year over year growth rate of 218%. The business is expected to report its next earnings report on Thursday, February 21st.

According to Zacks, analysts expect that Acorda Therapeutics will report full year earnings of $0.97 per share for the current financial year, with EPS estimates ranging from $0.50 to $1.84. For the next year, analysts forecast that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($4.54) to ($2.62). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.15. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The business had revenue of $142.80 million for the quarter, compared to analysts’ expectations of $82.74 million. During the same period in the prior year, the firm earned $0.43 earnings per share. Acorda Therapeutics’s revenue was up 1.2% compared to the same quarter last year.

Several research firms have recently commented on ACOR. Oppenheimer set a $18.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a research note on Sunday, September 23rd. Stifel Nicolaus decreased their price target on shares of Acorda Therapeutics from $25.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, October 5th. HC Wainwright set a $28.00 price objective on shares of Acorda Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 24th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Wednesday, January 2nd. Finally, ValuEngine raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 26th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $25.20.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp sold 52,891 shares of the stock in a transaction on Saturday, December 28th. The shares were sold at an average price of $14.99, for a total value of $792,836.09. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ron Cohen sold 3,620 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $20.60, for a total transaction of $74,572.00. Following the completion of the sale, the chief executive officer now owns 487,554 shares in the company, valued at $10,043,612.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,305,677 shares of company stock worth $22,536,747. Insiders own 7.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in Acorda Therapeutics by 87.3% in the third quarter. Renaissance Technologies LLC now owns 1,275,400 shares of the biopharmaceutical company’s stock worth $25,062,000 after purchasing an additional 594,500 shares during the period. GSA Capital Partners LLP acquired a new stake in Acorda Therapeutics in the third quarter worth $1,197,000. Quantbot Technologies LP acquired a new stake in Acorda Therapeutics in the third quarter worth $170,000. Advisory Services Network LLC acquired a new stake in shares of Acorda Therapeutics during the third quarter worth $365,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Acorda Therapeutics by 13.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 330,943 shares of the biopharmaceutical company’s stock worth $9,499,000 after acquiring an additional 38,414 shares during the period.

ACOR opened at $17.05 on Wednesday. Acorda Therapeutics has a one year low of $12.86 and a one year high of $36.35. The company has a current ratio of 4.03, a quick ratio of 3.95 and a debt-to-equity ratio of 0.57. The company has a market cap of $807.54 million, a PE ratio of 16.39 and a beta of 1.67.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Article: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply